Allogeneic Stem Cell Therapies
Allogeneic Stem Cell Therapies involve the use of stem cells sourced from a genetically non-identical donor, typically a matched sibling or unrelated donor. These therapies are widely used in treating blood disorders, cancers like leukemia, and immune system diseases. Allogeneic stem cells offer the advantage of being readily available for patients in need, but they also present challenges such as immune rejection and graft-versus-host disease (GVHD). Despite these hurdles, ongoing advancements in immunosuppression, genetic modification, and tissue matching are enhancing the safety and effectiveness of allogeneic stem cell therapies.
Related Conference of Allogeneic Stem Cell Therapies
September 24-25, 2026
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
Paris, France
November 16-17, 2026
19th International Conference on Human Genomics and Genomic Medicine
Tokyo, Japan
March 11-12, 2027
17th International Conference on Human Genetics and Genetic Diseases
Berlin, Germany
Allogeneic Stem Cell Therapies Conference Speakers
Recommended Sessions
- Dental Stem Cells
- Adult Stem Cells
- AI in Stem Cell Research
- Allogeneic Stem Cell Therapies
- Autologous Stem Cells Therapies
- Biotech Innovations
- Cancer Stem Cells
- Clinical Trials
- CRISPR and Gene Editing
- Nanotechnology and Stem Cells
- Neural Stem Cells
- Organoids Technology
- Pluripotent Stem Cells
- Stem Cell Banking and Preservation
- Stem Cell Bioprocessing
- Stem Cell Gene Therapy
- Stem Cell Therapy
- Stem Cell-Based Immunotherapies
- Stem Cells in Oral Health
- Tissue Engineering
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)
